{"id":"paliperidone-and-paliperidone-palmitate","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Extrapyramidal symptoms (akathisia, dystonia, parkinsonism)"},{"rate":"15-25","effect":"Weight gain"},{"rate":"20-40","effect":"Prolactin elevation"},{"rate":"10-20","effect":"Sedation"},{"rate":"5-15","effect":"Orthostatic hypotension"},{"rate":"5-10","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL2107360","moleculeType":"Small molecule","molecularWeight":"664.91"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paliperidone acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist, which helps normalize neurotransmitter activity in patients with psychotic disorders. Paliperidone palmitate is a long-acting injectable formulation of paliperidone that provides sustained drug release over weeks to months, improving medication adherence in schizophrenia and schizoaffective disorder.","oneSentence":"Paliperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:23.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Schizoaffective disorder"},{"name":"Bipolar I disorder (acute mania and maintenance)"}]},"trialDetails":[{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT05766007","phase":"","title":"Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-08-01","conditions":"Schizophrenia, Psychosis, Mania","enrollment":125},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT07268430","phase":"NA","title":"Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia","status":"COMPLETED","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2023-12-18","conditions":"Schizophrenia","enrollment":256},{"nctId":"NCT07075237","phase":"PHASE4","title":"Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2025-10","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT02634463","phase":"PHASE1","title":"Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-09","conditions":"Immunoassay, Antipsychotic","enrollment":81},{"nctId":"NCT04478838","phase":"PHASE4","title":"\"Extended\" (Alternate Day) Antipsychotic Dosing","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-06-06","conditions":"Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy","enrollment":120},{"nctId":"NCT03345342","phase":"PHASE3","title":"A Study of Paliperidone Palmitate 6-Month Formulation","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Schizophrenia","enrollment":841},{"nctId":"NCT04072575","phase":"PHASE3","title":"A Study of Paliperidone Palmitate 6-Month Formulation","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-19","conditions":"Schizophrenia","enrollment":178},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03713658","phase":"PHASE4","title":"A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-18","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT01819818","phase":"","title":"A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2011-05-23","conditions":"Schizophrenia","enrollment":3267},{"nctId":"NCT03809325","phase":"","title":"A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2018-11-21","conditions":"Schizophrenia","enrollment":225},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT00460512","phase":"PHASE3","title":"An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2007-04-25","conditions":"Schizophrenia","enrollment":1814},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT02713282","phase":"PHASE3","title":"A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2016-04-28","conditions":"Schizophrenia","enrollment":306},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT01527305","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06-22","conditions":"Schizophrenia","enrollment":212},{"nctId":"NCT01051531","phase":"PHASE3","title":"A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-04-22","conditions":"Schizophrenia","enrollment":546},{"nctId":"NCT05321602","phase":"PHASE1","title":"Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2021-09-08","conditions":"Schizophrenia, Psychotic Disorders, Mood Disorders","enrollment":89},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT06060886","phase":"PHASE4","title":"Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis","status":"UNKNOWN","sponsor":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","startDate":"2023-11-01","conditions":"Schizophrenia, Treatment-resistant Schizophrenia, Side Effect","enrollment":244},{"nctId":"NCT05473741","phase":"","title":"Risk of Breakthrough Symptoms With Long-Acting Injectable Medications","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-01-09","conditions":"Schizophrenia, Schizophrenia Relapse","enrollment":180},{"nctId":"NCT04922593","phase":"PHASE1","title":"Relative Bioavailability of LY03010 Compared to Listed Drug","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2021-01-13","conditions":"Schizophrenia, Psychotic Disorders, Mood Disorders","enrollment":281},{"nctId":"NCT01451736","phase":"PHASE4","title":"Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-10","conditions":"Schizophrenia (Recent-onset)","enrollment":146},{"nctId":"NCT01584466","phase":"NA","title":"Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2014-01","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT03019887","phase":"NA","title":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2011-04","conditions":"Schizophrenia Relapse","enrollment":139},{"nctId":"NCT04754750","phase":"PHASE1, PHASE2","title":"Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment","status":"COMPLETED","sponsor":"Calo Psychiatric Center","startDate":"2015-01","conditions":"Schizophrenics","enrollment":72},{"nctId":"NCT04572685","phase":"PHASE1","title":"Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2020-01-22","conditions":"Schizophrenia Patients","enrollment":36},{"nctId":"NCT02146547","phase":"PHASE4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Schizophrenia","enrollment":536},{"nctId":"NCT03345979","phase":"PHASE3","title":"A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2017-11-15","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT04064476","phase":"","title":"The Effect of Long-acting Antipsychotics on Schizophrenia Patients With Violence Risk","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2019-08-18","conditions":"Schizophrenia","enrollment":225},{"nctId":"NCT02085447","phase":"NA","title":"A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2014-05","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":30},{"nctId":"NCT03434210","phase":"NA","title":"The Effect of a Community-based LAT-treated Management Model on the Violence Risk of Patients With Schizophrenia","status":"UNKNOWN","sponsor":"Yi Li MD, PhD","startDate":"2018-05-05","conditions":"Schizophrenia","enrollment":110},{"nctId":"NCT03425552","phase":"PHASE1, PHASE2","title":"A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment","status":"COMPLETED","sponsor":"Pharmathen S.A.","startDate":"2018-03-11","conditions":"Schizophrenia","enrollment":70},{"nctId":"NCT02472652","phase":"PHASE4","title":"Aripiprazole, Abilify Maintena Collaborative Clinical Protocol","status":"TERMINATED","sponsor":"Gazda, Thomas D., M.D., PC","startDate":"2015-06","conditions":"Sexual Dysfunction","enrollment":2},{"nctId":"NCT02600741","phase":"","title":"Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-24","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT02634320","phase":"PHASE4","title":"A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-12","conditions":"Schizophrenia","enrollment":51},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":"Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders","enrollment":21},{"nctId":"NCT01411085","phase":"PHASE2","title":"Risperidone and Desipramine in Alcohol Use and Schizophrenia","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2011-12","conditions":"Schizophrenia, Alcoholism, Dual Diagnosis","enrollment":12},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02918825","phase":"NA","title":"Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2016-09-01","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT03390712","phase":"","title":"Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection","status":"UNKNOWN","sponsor":"Réseau de Santé Vitalité Health Network","startDate":"2018-01-02","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":328},{"nctId":"NCT01559272","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2008-02-21","conditions":"Schizophrenia","enrollment":328},{"nctId":"NCT00549562","phase":"PHASE3","title":"Study of Paliperidone ER in Adolescents and Young Adults With Autism","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2007-11","conditions":"Autism","enrollment":25},{"nctId":"NCT03080194","phase":"PHASE4","title":"The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia","status":"UNKNOWN","sponsor":"Maosheng Fang","startDate":"2017-04","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT02462473","phase":"PHASE2","title":"A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":9},{"nctId":"NCT01795547","phase":"PHASE3","title":"Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-02","conditions":"Schizophrenia","enrollment":295},{"nctId":"NCT00766064","phase":"PHASE4","title":"Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2008-09","conditions":"Posttraumatic Stress Disorder","enrollment":""},{"nctId":"NCT01515423","phase":"PHASE3","title":"Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-05","conditions":"Schizophrenia","enrollment":1429},{"nctId":"NCT01670071","phase":"PHASE4","title":"A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia","status":"TERMINATED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2013-01","conditions":"Schizophrenia","enrollment":17},{"nctId":"NCT01947803","phase":"PHASE4","title":"A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2013-09","conditions":"Schizophrenia","enrollment":353},{"nctId":"NCT01362426","phase":"","title":"Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)","status":"COMPLETED","sponsor":"Janssen-Cilag Pty Ltd","startDate":"2011-03","conditions":"Schizophrenia","enrollment":127},{"nctId":"NCT01134731","phase":"PHASE4","title":"Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2010-05","conditions":"Major Depressive Disorder, Suicidal Ideation","enrollment":54},{"nctId":"NCT01050478","phase":"PHASE4","title":"IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation","status":"COMPLETED","sponsor":"Janssen Cilag N.V./S.A.","startDate":"2010-03","conditions":"Psychomotor Agitation, Acute Disease","enrollment":56},{"nctId":"NCT01685931","phase":"PHASE4","title":"A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2012-11","conditions":"Schizophrenia","enrollment":617},{"nctId":"NCT01698216","phase":"","title":"Switching From Consta® to Sustenna® in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-12","conditions":"Schizophrenia","enrollment":50},{"nctId":"NCT02433717","phase":"PHASE4","title":"A Pharmacokinetic Study of Paliperidone ER","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2015-04","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":40},{"nctId":"NCT02532842","phase":"","title":"Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2015-07","conditions":"Schizophrenia","enrollment":90},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":725489},{"nctId":"NCT02541513","phase":"PHASE3","title":"An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence","status":"UNKNOWN","sponsor":"Universiti Sains Malaysia","startDate":"2013-05","conditions":"Heroin Dependence, Amphetamine Dependence","enrollment":40},{"nctId":"NCT01926912","phase":"","title":"A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-05","conditions":"Schizophrenia","enrollment":371},{"nctId":"NCT01157585","phase":"PHASE4","title":"Efficacy and Safety of Paliperidone ER in First Episode Psychosis","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2010-02","conditions":"First Episode Psychosis","enrollment":75},{"nctId":"NCT01157351","phase":"PHASE4","title":"15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2010-05","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT00490971","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-05","conditions":"Bipolar Disorder","enrollment":768},{"nctId":"NCT01081769","phase":"PHASE3","title":"Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2010-02","conditions":"Schizophrenia","enrollment":769},{"nctId":"NCT01822730","phase":"PHASE4","title":"A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis","status":"COMPLETED","sponsor":"Wei Hao","startDate":"2013-02","conditions":"Methamphetamine Dependence","enrollment":120},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT01211704","phase":"PHASE4","title":"Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2010-10","conditions":"Bipolar Disorder","enrollment":""},{"nctId":"NCT01450514","phase":"PHASE2","title":"POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia","status":"COMPLETED","sponsor":"PharmaNeuroBoost N.V.","startDate":"2012-03","conditions":"Chronic Schizophrenia, Schizoaffective Disorder","enrollment":7},{"nctId":"NCT01662310","phase":"PHASE3","title":"An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-06","conditions":"Schizophrenia","enrollment":201},{"nctId":"NCT01448720","phase":"PHASE3","title":"Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2011-09","conditions":"Schizophrenia","enrollment":142},{"nctId":"NCT01682161","phase":"PHASE4","title":"A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2012-01","conditions":"Schizophrenia","enrollment":154},{"nctId":"NCT00535145","phase":"PHASE4","title":"Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2007-10","conditions":"Schizophrenia, Schizoaffective Disorder, Psychotic Disorders","enrollment":121},{"nctId":"NCT01258920","phase":"PHASE3","title":"A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2010-10","conditions":"Schizophrenia","enrollment":201},{"nctId":"NCT00589914","phase":"PHASE3","title":"Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-03","conditions":"Schizophrenia","enrollment":1221},{"nctId":"NCT00309699","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-04","conditions":"Bipolar Disorder, Mood Disorders","enrollment":493},{"nctId":"NCT00590577","phase":"PHASE3","title":"Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-03","conditions":"Schizophrenia","enrollment":652},{"nctId":"NCT00524043","phase":"PHASE4","title":"An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-09","conditions":"Schizophrenia","enrollment":201},{"nctId":"NCT00761579","phase":"PHASE4","title":"Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2008-04","conditions":"Schizophrenia","enrollment":190},{"nctId":"NCT01150448","phase":"PHASE1","title":"A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-09","conditions":"Schizophrenia","enrollment":212},{"nctId":"NCT00412373","phase":"PHASE3","title":"Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-12","conditions":"Schizoaffective Disorder, Psychotic Disorder","enrollment":307},{"nctId":"NCT00645099","phase":"PHASE3","title":"A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2007-10","conditions":"Schizophrenia","enrollment":462},{"nctId":"NCT01662648","phase":"PHASE3","title":"Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Pharmaceutica","startDate":"2007-06","conditions":"Schizophrenia","enrollment":1117},{"nctId":"NCT00697658","phase":"","title":"INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen-Cilag B.V.","startDate":"2008-03","conditions":"Schizophrenia","enrollment":27},{"nctId":"NCT00518323","phase":"PHASE3","title":"A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-08","conditions":"Schizophrenia","enrollment":201},{"nctId":"NCT00784238","phase":"PHASE4","title":"Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2008-04","conditions":"Schizophrenia","enrollment":289},{"nctId":"NCT01281527","phase":"PHASE3","title":"Paliperidone Palmitate Flexible Dosing in Schizophrenia","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2010-11","conditions":"Schizophrenia","enrollment":1044},{"nctId":"NCT00761189","phase":"PHASE4","title":"PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2008-02","conditions":"Schizophrenia","enrollment":491},{"nctId":"NCT02075528","phase":"PHASE4","title":"Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER","status":"COMPLETED","sponsor":"Taipei City Hospital","startDate":"2009-07","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":41},{"nctId":"NCT01181960","phase":"","title":"Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2010-08","conditions":"Schizophrenia, Bipolar Disorder","enrollment":1066},{"nctId":"NCT00934635","phase":"PHASE4","title":"A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls","status":"TERMINATED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2009-09","conditions":"Schizophrenia","enrollment":2},{"nctId":"NCT00757705","phase":"PHASE4","title":"An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2008-03","conditions":"Schizophrenia","enrollment":299},{"nctId":"NCT00632229","phase":"PHASE2","title":"Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2007-10","conditions":"Obsessive-Compulsive Disorder","enrollment":34},{"nctId":"NCT01577186","phase":"PHASE4","title":"Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2008-07","conditions":"Schizophrenia","enrollment":480},{"nctId":"NCT01577160","phase":"PHASE4","title":"A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2008-05","conditions":"Schizophrenia","enrollment":353},{"nctId":"NCT00915512","phase":"PHASE4","title":"A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Janssen-Cilag Turkey","startDate":"2009-05","conditions":"Schizophrenia","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":690,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Paliperidone: Invega®","Paliperidone palmitate: Xeplion® or Invega® Sustenna®"],"phase":"phase_3","status":"active","brandName":"Paliperidone and paliperidone palmitate","genericName":"Paliperidone and paliperidone palmitate","companyName":"H. Lundbeck A/S","companyId":"h-lundbeck-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paliperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms. Used for Schizophrenia, Schizoaffective disorder, Bipolar I disorder (acute mania and maintenance).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}